ZA200005553B - Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors. - Google Patents

Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors.

Info

Publication number
ZA200005553B
ZA200005553B ZA200005553A ZA200005553A ZA200005553B ZA 200005553 B ZA200005553 B ZA 200005553B ZA 200005553 A ZA200005553 A ZA 200005553A ZA 200005553 A ZA200005553 A ZA 200005553A ZA 200005553 B ZA200005553 B ZA 200005553B
Authority
ZA
South Africa
Prior art keywords
methods
compositions
combination
leukotriene inhibitors
terfenadine
Prior art date
Application number
ZA200005553A
Other languages
English (en)
Inventor
Paul D Rubin
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of ZA200005553B publication Critical patent/ZA200005553B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200005553A 1998-04-14 2000-10-10 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors. ZA200005553B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/059,570 US6194431B1 (en) 1998-04-14 1998-04-14 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors

Publications (1)

Publication Number Publication Date
ZA200005553B true ZA200005553B (en) 2001-05-17

Family

ID=22023833

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200005553A ZA200005553B (en) 1998-04-14 2000-10-10 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors.

Country Status (21)

Country Link
US (4) US6194431B1 (xx)
EP (2) EP1071463B1 (xx)
JP (1) JP2002511426A (xx)
KR (1) KR100686297B1 (xx)
CN (2) CN1768749A (xx)
AT (1) ATE328608T1 (xx)
AU (1) AU763979B2 (xx)
BR (1) BR9909641A (xx)
CA (1) CA2328074C (xx)
CY (1) CY1106800T1 (xx)
DE (1) DE69931771T2 (xx)
DK (1) DK1071463T3 (xx)
ES (1) ES2260910T3 (xx)
HU (1) HU228035B1 (xx)
IL (2) IL138993A0 (xx)
NO (1) NO20005147L (xx)
NZ (1) NZ507762A (xx)
PL (1) PL343526A1 (xx)
PT (1) PT1071463E (xx)
WO (1) WO1999052554A1 (xx)
ZA (1) ZA200005553B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US20020198246A1 (en) * 1998-09-30 2002-12-26 Ono Pharmaceutical Co., Ltd. Agent for preventing and/or treating sinusitis
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US6440994B1 (en) 2000-03-29 2002-08-27 Richard J. Sanders, Jr. Method of treating acne
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
AU2003237253A1 (en) * 2002-05-29 2003-12-19 Aventis Pharmaceuticals Holdings Inc. Method of treating asthma using fexofenadine
US20040115647A1 (en) * 2002-12-12 2004-06-17 Paterson Thomas S. Apparatus and method for identifying biomarkers using a computer model
WO2009027852A2 (en) * 2007-08-28 2009-03-05 Agi Therapeutics, P.L.C. Methods and compositions for treating gastrointestinal conditions
WO2016011254A1 (en) * 2014-07-16 2016-01-21 Henry J. Legere Md, Pa Combinations of antihistamines and leukotriene antagonists and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878217A (en) 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4617407A (en) * 1984-08-30 1986-10-14 Merck Frosst Canada, Inc. Leukotriene antagonists
US4742175A (en) 1986-05-07 1988-05-03 Merrell Dow Pharmaceuticals Inc. Preparation of polymorphically pure terfenadine
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4929605A (en) 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US4996061A (en) 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
CN1053570C (zh) 1987-10-07 2000-06-21 默尔多药物公司 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US4990259A (en) 1988-12-16 1991-02-05 The Amalgamated Sugar Company Chromatographic separator sorbent bed preparation
US5019591A (en) 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
JPH07506828A (ja) 1992-05-11 1995-07-27 メレルダウファーマス−ティカルズ　インコーポレイテッド 肝臓が損われた患者での抗ヒスタミン剤としてのターフェナジン誘導体の用途
JP3041954B2 (ja) 1992-08-03 2000-05-15 セプラコア インコーポレーテッド アレルギー疾患治療用のテルフェナジン代謝物及びその光学的に純粋な異性体
AU670004B2 (en) 1993-06-24 1996-06-27 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
WO1995010278A1 (en) 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
JPH11507670A (ja) * 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
CA2245162A1 (en) 1996-02-08 1997-08-14 Merck & Co., Inc. Method of treatment and pharmaceutical composition
ES2169351T3 (es) * 1996-02-13 2002-07-01 Searle & Co Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
CA2315721C (en) * 1997-12-23 2008-08-12 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors

Also Published As

Publication number Publication date
DE69931771T2 (de) 2006-10-12
CA2328074C (en) 2012-02-21
US20120149730A1 (en) 2012-06-14
US6194431B1 (en) 2001-02-27
NZ507762A (en) 2003-09-26
BR9909641A (pt) 2000-12-19
US8404715B2 (en) 2013-03-26
EP1071463A1 (en) 2001-01-31
PT1071463E (pt) 2006-10-31
ES2260910T3 (es) 2006-11-01
KR20010042655A (ko) 2001-05-25
AU763979B2 (en) 2003-08-07
AU3640999A (en) 1999-11-01
US6509353B1 (en) 2003-01-21
CY1106800T1 (el) 2012-05-23
JP2002511426A (ja) 2002-04-16
HU228035B1 (en) 2012-08-28
IL138993A0 (en) 2001-11-25
HUP0102239A2 (hu) 2002-03-28
HUP0102239A3 (en) 2002-06-28
ATE328608T1 (de) 2006-06-15
CN1768749A (zh) 2006-05-10
NO20005147L (no) 2000-11-07
CN1305385A (zh) 2001-07-25
CA2328074A1 (en) 1999-10-21
DK1071463T3 (da) 2006-09-25
IL138993A (en) 2011-01-31
DE69931771D1 (de) 2006-07-20
US20030083343A1 (en) 2003-05-01
WO1999052554A1 (en) 1999-10-21
KR100686297B1 (ko) 2007-02-23
EP1707216A1 (en) 2006-10-04
PL343526A1 (en) 2001-08-27
NO20005147D0 (no) 2000-10-13
EP1071463B1 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
AU8003800A (en) Methods and compositions for treating neurobehavioral disorders
EP1769797A3 (en) Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition
IL155795A0 (en) Combination of drugs (e.g. chlorpromazine and pentamidine) for the treatment of neoplastic disorders
TW200507830A (en) Bronchodilating β -agonist compositions and methods
WO2005046434A8 (en) Compositions and methods for diagnosing and treating mental disorders
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2001245977A1 (en) Method and composition for preventing or reducing the symptoms of menopause
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
CY1106800T1 (el) Μεθοδοι και συνθεσεις δια χρησιμοποιησεως μεταβολιτων τepφεναδινης εν συνδυασμω μετ’ αναστολεων λευκοτριενιου
WO2003039490A9 (en) Compositions and methods for diagnosing and treating mental disorders
EP1723957A3 (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
IL159006A0 (en) Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same
MY106885A (en) Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
AU2003259246A1 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
ITRM990707A0 (it) Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil l-carni
AU2002312314A1 (en) Compositions and methods for preventing neural tube disorders
HUP0204209A3 (en) Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms
AUPQ872800A0 (en) Compositions and methods for treating cardiovascular disorders
AUPS255402A0 (en) Agents and methods for the treatment of disorders associated with oxidative stress
AU2002348281A1 (en) Compositions and methods for diagnosing and treating mental disorders
AU3924500A (en) Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
AU2002361711A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS USING 252, 304, 19870, 14717, 9941, 19310 and 17832
GB0216220D0 (en) The treatment of emesis nausea and other disorders
AU2002359362A1 (en) Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
WO2003020310A1 (fr) Moyens de prevention et/ou de traitement de maladies causees par des troubles de la microcirculation endo-osseuse